Re: Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal
“NKTR-214 and Nivo combo cannot provide stronger benefits as compared to current IO-TKI combos in RCC”
How are you determining that? 1L RCC ORR was 71.4% (10/14; 7.1% CR, 64.3% PR) and ORR of 28.6% (2/7, all PRs) in 2L I-O naive pts. It’s early data, with small n.
Total ORR was 59.5%, CR was 18.9%, and DCR 83.8%
ORR in PD-L1+ and PD-L1- patients was respectively 64.7% and 50.0%